Evidence map›Paper›PMID 28850760›Full record

ReviewDevelopmental dynamics : an official publication of the American Association of Anatomists2018

MicroRNA-induced silencing in epilepsy: Opportunities and challenges for clinical application.

Durgesh Tiwari, Katrina Peariso, Christina Gross

Open access · bronzeAbstract readReview
In one paragraph

Review in Developmental dynamics : an official publication of the American Association of Anatomists, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Therapeutic Implications of microRNAs in Depressive Disorders: A Review.International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Durgesh TiwariCincinnati Children's Hospital Medical Center, Division of Neurology, Cincinnati, Ohio.
Katrina PearisoCincinnati Children's Hospital Medical Center, Division of Neurology, Cincinnati, Ohio.
Christina GrossCincinnati Children's Hospital Medical Center, Division of Neurology, Cincinnati, Ohio.ORCID 0000-0001-6057-2527
Cincinnati Children's Hospital Medical Center · US

Funding

MicroRNA-mediated silencing of the Kv4.2 complex in epilepsyR01NS092705 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI GROSS, CHRISTINA · 2016 to 2020
$1.8M
NINDS NIH HHS R01 NS092705
6 · The paper itself

Abstract

MicroRNAs are master regulators of gene expression. Single microRNAs influence multiple proteins within diverse molecular pathways and networks. Therefore, changes in levels or activity of microRNAs can have profound effects on cellular function. This makes dysregulated microRNA-induced silencing an attractive potential disease mechanism in complex disorders like epilepsy, where numerous cellular pathways and processes are affected simultaneously. Indeed, several years of research in rodent models have provided strong evidence that acute or recurrent seizures change microRNA expression and function. Moreover, altered microRNA expression has been observed in brain and blood from patients with various epilepsy disorders, such as tuberous sclerosis. MicroRNAs can be easily manipulated using sense or antisense oligonucleotides, opening up opportunities for therapeutic intervention. Here, we summarize studies using these techniques to identify microRNAs that modulate seizure susceptibility, describe protein targets mediating some of these effects, and discuss cellular pathways, for example neuroinflammation, that are controlled by epilepsy-associated microRNAs. We critically assess current gaps in knowledge regarding target- and cell-specificity of microRNAs that have to be addressed before clinical application as therapeutic targets or biomarkers. The recent progress in understanding microRNA function in epilepsy has generated strong momentum to encourage in-depth mechanistic studies to develop microRNA-targeted therapies. Developmental Dynamics 247:94-110, 2018. © 2017 Wiley Periodicals, Inc.

Indexed as

Gene SilencingAnimalsBrainEpilepsyHumansMicroRNAsOligonucleotides, AntisenseMicroRNAsOligonucleotides, AntisensemiRNAneuroinflammationRISCseizurestatus epilepticustherapytuberous sclerosis

Identifiers

PMID28850760
PMCPMC5740004
OpenAlexW2751861194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.